Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 1:384:10-17.
doi: 10.1016/j.ijcard.2023.04.046. Epub 2023 Apr 26.

Single-pill combination in the management of chronic coronary syndromes: A strategy to improve treatment adherence and patient outcomes?

Fausto J Pinto  1 , Massimo F Piepoli  2 , Roberto Ferrari  3 , Konstantinos Tsioufis  4 , Giuseppe M C Rosano  5 , Aleksandr Nedoshivin  6 , Juan Carlos Kaski  7
Affiliations
Free article
Review

Single-pill combination in the management of chronic coronary syndromes: A strategy to improve treatment adherence and patient outcomes?

Fausto J Pinto et al. Int J Cardiol. .
Free article

Abstract

Chronic coronary syndrome (CCS) represents a major challenge for physicians, particularly in the context of an increasing aging population. Additionally, CCS is often underestimated and under-recognised, particularly in female patients. As patients are frequently affected by several chronic comorbidities requiring polypharmacy, this can have a negative impact on patients' adherence to treatment. To overcome this barrier, single-pill combination (SPC), or fixed-dose combination, therapies are already widely used in the management of conditions such as hypertension, dyslipidaemia, and diabetes mellitus. The use of SPC anti-anginal therapy deserves careful consideration, as it has the potential to substantially improve treatment adherence and clinical outcomes, along with reducing the failure of pharmacological treatment before considering other interventions in patients with CCS.

Keywords: Adherence; Angina; Chronic coronary syndrome; Comorbidities; Single-pill combination; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest F.P. reports receiving consulting fees and/or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Daiichi Sankyo, Novartis, Servier, and Vifor, participates on a Data Safety Monitoring Board or Advisory Board for Vifor, and is President of the World Heart Federation. M.F.P. reports receiving honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AstraZeneca, Menarini, and Novartis, participates on a Data Safety Monitoring Board or Advisory Board for CHF solution, is Vice President of the European Society of Cardiology, and is a Board Member of the Heart Failure Association and the European Association of Preventive Cardiology. R.F. reports receiving honoraria/travel expenses for lectures, presentations, speakers bureaus, manuscript writing or educational from Novartis, Merck Serono, Lupin, Servier, Sun Pharma, and Reddys Limited, is a Scientific Director at Medical Trial Analysis, a Director at Art Research and Science Srl, is a Past President of the ESC, and is an Honorary member of the International Cardiology Society, British, French, Argentine, and Czech Society of Cardiology, and Heart Association of Thailand. K.T. reports receiving honoraria or research grants for advisory boards and lectures from Recor, Recordati, Medtronic, Servier, Bayer, Menarini, Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer, Chiesi, Pharmanel, Sanofi, Amgen, and ELPEN, and was a Task Force Member for the 2018 ESC/ESH hypertension guidelines. G.R. reports no conflict of interest. A.N. reports receiving honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Servier and Berlin Chemie AG. J.C.K. reports receiving speaker honoraria and travel expenses from A. Menarini Farmaceutica Internazionale SRL (UK) and is a Medical Director at Glycardial Diagnostics SL.

References